Compare Paychex, Inc. (PAYX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Smith & Nephew plc — how do they compare? Paychex, Inc. trades at $104.15 (market cap $37.19B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Paychex, Inc. is far larger — about 3.4× Smith & Nephew plc's market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Smith & Nephew plc for 121 Days on average.
| PAYX | SNN | |
|---|---|---|
Market Cap | $37.19B | $11.10B |
Volume | 3,344,316 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $128.59 | $37.17 |
52-Week Low | $85.57 | $26.42 |
Typical Hold Time | 56 Days | 121 Days |
Enterprise Value | $40.87B | $14.13B |
Dividend Yield | 4.56% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.62, up 3.02% today, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.34 beating the $1.32 estimate, and maintains robust profitability with a 27.35% net income margin. Recent news highlights a 14% stock decline despite earnings strength, raising questions about dividend sustainability amid investor focus on cash flow.
The outlook is cautiously optimistic, with a consensus price target of $111 suggesting modest upside. Key opportunities include steady revenue growth and high margins, but risks involve labor market sensitivity and elevated valuation multiples. The stock's recent volatility reflects divergent analyst views, with 67.74% holding a neutral rating.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
